Hjem
Universitetet i Bergen
Anette Susanne Bøe Wolffs bilde

Anette Susanne Bøe Wolff

Gjesteforsker
Klinisk institutt 2
  • E-postanette.boe@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 sider.
  • Vis forfatter(e) (2023). Th17 Cells: Orchestrators of Mucosal Inflammation and Potential Therapeutic Targets. Critical Reviews in Immunology. 25-52.
  • Vis forfatter(e) (2023). Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1. FEBS Letters. 1261-1274.
  • Vis forfatter(e) (2023). Systemic Activation of the Kynurenine Pathway in Graves Disease With and Without Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism (JCEM). 1290-1297.
  • Vis forfatter(e) (2023). A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies. Journal of Internal Medicine. 96-109.
  • Vis forfatter(e) (2023). A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation.
  • Vis forfatter(e) (2022). Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. Journal of Autoimmunity. 1-?.
  • Vis forfatter(e) (2021). Vitamin D status and pathway genes in five European autoimmune Addison's disease cohorts. European Journal of Endocrinology (EJE). 373-381.
  • Vis forfatter(e) (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
  • Vis forfatter(e) (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
  • Vis forfatter(e) (2021). Potential Transcriptional Biomarkers to Guide Glucocorticoid Replacement in Autoimmune Addison's Disease. Journal of the Endocrine Society (JES). 1-10.
  • Vis forfatter(e) (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
  • Vis forfatter(e) (2021). 21-Hydroxylase-Specific CD8+ T Cells in Autoimmune Addison’s Disease Are Restricted by HLA-A2 and HLA-C7 Molecules. Frontiers in Immunology. 12 sider.
  • Vis forfatter(e) (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • Vis forfatter(e) (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • Vis forfatter(e) (2018). Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
  • Vis forfatter(e) (2017). Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I. Autoimmunity. 211-222.
  • Vis forfatter(e) (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
  • Vis forfatter(e) (2017). Autoantibody repertoire in APECED patients targets two distinct subgroups of proteins. Frontiers in Immunology.
  • Vis forfatter(e) (2017). Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins. Frontiers in Immunology.
  • Vis forfatter(e) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Vis forfatter(e) (2016). AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. Cell. 582-595.
  • Vis forfatter(e) (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
  • Vis forfatter(e) (2015). Linkage analysis in autoimmune Addison's disease: NFATC1 as a potential novel susceptibility locus. PLOS ONE.
  • Vis forfatter(e) (2015). Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6. Endocrine Connections. 215-222.
  • Vis forfatter(e) (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • Vis forfatter(e) (2015). CTLA-4 as a genetic determinant in autoimmune Addison's disease. Genes and Immunity. 430-436.
  • Vis forfatter(e) (2014). Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. Endocrine Connections. 67-74.
  • Vis forfatter(e) (2014). Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
  • Vis forfatter(e) (2014). CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles. European Journal of Endocrinology (EJE). 743-750.
  • Vis forfatter(e) (2014). Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European Cohorts. PLOS ONE.
  • Vis forfatter(e) (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
  • Vis forfatter(e) (2013). Screening for X-linked adrenoleukodystrophy among adult men with Addison's disease. Clinical Endocrinology. 316-320.
  • Vis forfatter(e) (2013). Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity. Immunobiology. 899-909.
  • Vis forfatter(e) (2013). Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clinical and Experimental Immunology. 263-272.
  • Vis forfatter(e) (2013). Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
  • Vis forfatter(e) (2012). Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
  • Vis forfatter(e) (2012). Autoimmune polyendocrine syndrome Type 1: an Eetensive longitudinal study in Sardinian patients. Journal of Clinical Endocrinology and Metabolism (JCEM). 1114-1124.
  • Vis forfatter(e) (2011). Multiple loci in the HLA complex are associated with Addison's Disease. Journal of Clinical Endocrinology and Metabolism (JCEM). E1703-E1708.
  • Vis forfatter(e) (2011). Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
  • Vis forfatter(e) (2011). Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. European Journal of Endocrinology (EJE). 345-352.
  • Vis forfatter(e) (2011). Genome-wide copy number variation (CNV) in patients with autoimmune Addison's disease. BMC Medical Genetics. 6 sider.
  • Vis forfatter(e) (2010). Novel sequence variation of AIRE and detection of interferon-ω antibodies in early infancy. Clinical Endocrinology. 641-647.
  • Vis forfatter(e) (2010). Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
  • Vis forfatter(e) (2010). Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. Journal of Experimental Medicine (JEM). 299-308.
  • Vis forfatter(e) (2009). Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility. Journal of Clinical Endocrinology and Metabolism (JCEM). 5139-5145.
  • Vis forfatter(e) (2009). Programmed Death Ligand 1 (PD-L1) Gene Variants Contribute to Autoimmune Addison’s Disease and Graves’ Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism (JCEM). 5139-5145.
  • Vis forfatter(e) (2009). Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. European Journal of Endocrinology (EJE). 993-1002.
  • Vis forfatter(e) (2009). Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry. Journal of Clinical Endocrinology and Metabolism (JCEM). 4882-4890.
  • Vis forfatter(e) (2009). A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity. 120-124.
  • Vis forfatter(e) (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • Vis forfatter(e) (2008). Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism (JCEM). 3310-3317.
  • Vis forfatter(e) (2008). Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. European Journal of Human Genetics. 977-982.
  • Vis forfatter(e) (2008). Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood. 2657-2666.
  • Vis forfatter(e) (2008). Autoimmune polyendocrine syndrome type I in Slovakia: relevance of screening patients with autoimmune Addison's disease. European Journal of Endocrinology (EJE). 705-709.
  • Vis forfatter(e) (2008). Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. Journal of Clinical Endocrinology and Metabolism (JCEM). 4389-4397.
  • Vis forfatter(e) (2008). AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
  • Vis forfatter(e) (2007). Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
  • Vis forfatter(e) (2007). Epitope mapping of human aromatic L-amino acid decarboxylase. Biochemical and Biophysical Research Communications - BBRC. 692-698.
  • Vis forfatter(e) (2007). Autoimmune polyendocrine syndrome type 1 in Norway: Phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. Journal of Clinical Endocrinology and Metabolism (JCEM). 595-603.
  • Vis forfatter(e) (2004). Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system. British Journal of Cancer. 1508-1514.
  • Vis forfatter(e) (2004). Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. European Journal of Endocrinology (EJE). 49-56.
  • Vis forfatter(e) (2000). Inhibition of aromatic 1-amino acid decarboxylase by human autoantibodies. Clinical and Experimental Immunology. 420-423.
  • Vis forfatter(e) (1996). Open tibial fractures treated with the Ex-fi-re external system. Clinical Orthopaedics and Related Research. 209-220.
  • Vis forfatter(e) (1996). Lumbale skiveprolapser hos ungdom. Tidsskrift for Den norske legeforening. 2993-2995.
  • Vis forfatter(e) (1992). Albueartroskopi. Tidsskrift for Den norske legeforening. 493-494.
Rapport
  • Vis forfatter(e) (2014). Samhandling mellom Røde Kors Haugland Rehabiliteringssenter, NAV og primærhelsetenesta i heile rehabiliteringsforløpet. .
Fagbok
  • Vis forfatter(e) (1995). Hyperbaric medical emergency service. Evaluation of equipment, procedures and techniques. NUTEC Report 5-95. [Mangler utgivernavn].
Doktorgradsavhandling
  • Vis forfatter(e) (2019). Exploring and redefining Autoimmune polyendocrine syndrome type 1.
  • Vis forfatter(e) (2005). Immunological perspectives of autoimmune polyendocrine syndromes and cancer.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2019). The Natural History of APS1. 7 sider.
  • Vis forfatter(e) (2019). Aire Mutations and Autoimmune Diseases. 24 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Human leukocyte antigen (DQ2/DQ8) and 21-hydroxylase antibodies determine the thyroid peroxidase antibody status of patients in autoimmune Addison's disease. Experimental and clinical endocrinology & diabetes. 2 sider.
  • Vis forfatter(e) (2013). Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
  • Vis forfatter(e) (2013). Characterisation of the CYP21A2 Gene in Patients with Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 310-310.
  • Vis forfatter(e) (2012). Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyedocrine sydnrome type I. Immunology. 673-674.
  • Vis forfatter(e) (2012). Increased anti-cytokine autoantibodies without disease manifestion in a 4 year-old boy with autoimmune polyendocrine syndrome )APS)-1. Journal of Clinical Immunology. 110-111.
  • Vis forfatter(e) (2012). Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
  • Vis forfatter(e) (2011). Cytokine Antibodies in Autoimmune Polyendocrine Syndrome Type I Correlates to Chronic candidiasis. Scandinavian Journal of Immunology. 379-379.
  • Vis forfatter(e) (2010). Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
  • Vis forfatter(e) (2007). Epitope mapping of human aromatic L-amino acid decarboxylase. Scandinavian Journal of Immunology. 592-592.
Poster
  • Vis forfatter(e) (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2021). B cells and autoantibodies in aire deficiency. Biomedicines. 1-15.
  • Vis forfatter(e) (2020). The prospects of single-cell analysis in autoimmunity. Scandinavian Journal of Immunology. 1-15.
  • Vis forfatter(e) (2020). New ERA of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology. 1-23.
  • Vis forfatter(e) (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology. 8-15.

Se fullstendig oversikt over publikasjoner i CRIStin.